MedTrace Logo

A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis

NCT06972888 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2025-05-22

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and safety of AC-201 tablets compared with placebo in subjects with moderate-to-severe plaque psoriasis

Conditions

Interventions

DRUG

AC-201

AC-201 tablets will be administered orally

DRUG

Placebo

Matching placebo tablets will be administered orally.

Sponsors & Collaborators

  • Accro Bioscience (Suzhou) Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-23
Primary Completion
2025-03-07
Completion
2025-04-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06972888 on ClinicalTrials.gov